Follicular Lymphoma
News
Drug shows early promise for rel/ref NHL
Blinatumomab, a CD19/CD3 bispecific T-cell engager antibody construct, can produce durable responses in patients with relapsed/refractory B-cell...
News
EMA recommends safety measures for idelalisib
Photo courtesy of Gilead Sciences, Inc. In light of recently reported safety concerns, the European Medicines Agency’s (EMA) Pharmacovigilance...
News
Idelalisib use halted in six combo therapy trials, FDA announces
News
AEs prompt EMA review of idelalisib
Photo courtesy of Gilead Sciences, Inc. The European Medicines Agency (EMA) is reviewing the safety of idelalisib (Zydelig), a drug approved to...
News
Follicular lymphoma: Quantitative PET/CT measures for detecting bone marrow involvement
Key clinical point: Measuring the mean standardized uptake value of 18fluorodeoxyglucose in the bone marrow of patients with follicular lymphoma...
News
Germline mutations linked to hematologic malignancies
A new study suggests mutations in the gene DDX41 occur in families where hematologic malignancies are common. Previous research showed that both...
News
Teens’ weight, height linked to risk of NHL
A new analysis indicates that having a higher body weight and taller stature during adolescence may increase the risk of developing non-Hodgkin...
News
NICE issues draft guideline for NHL
a cancer patient Photo courtesy of NCI/ Mathews Media Group The National Institute for Health and Care Excellence (NICE) has issued a draft...
News
Mutations could be therapeutic target for FL
Mutations in the RRAGC gene appear to be an “excellent candidate for therapeutic targeting” in follicular lymphoma (FL), according to...
Conference Coverage
EZH2 inhibitor can produce durable responses
ORLANDO, FL—Updated results of a phase 1 study suggest the EZH2 inhibitor tazemetostat (EPZ-6438) can produce durable responses in patients with...
Conference Coverage
Triplet disappoints in follicular lymphoma trial
Photo courtesy of ASH ORLANDO, FL—A 3-drug regimen is likely not worth pursuing as a first-line treatment option for follicular lymphoma (FL),...